Rona Yaeger, MD
Gastrointestinal Medical Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
About Me
- Attending Physician
I am a medical oncologist who specializes in treating people with cancers of the colon and rectum. I also care for people with anal squamous cell cancer, carcinoid tumors, and other gastrointestinal tract cancers.
Read more
My clinical and laboratory research at Memorial Sloan Kettering center on understanding molecular subsets of colorectal cancer and developing new therapies based on this understanding. My work focuses on colorectal tumors with mutations in the BRAF or RAS genes, and I am leading our clinical trial program for colorectal tumors that harbor BRAF mutations. I both treat patients and perform laboratory research and believe that my experiences in each realm inform my work and make me a better researcher. Ultimately, I aim to use our insights into cancer cell biology to help guide the care of our patients and to develop more rationally designed clinical trials that test mechanism-based therapeutic strategies.
A gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Colorectal Cancer
- Gastrointestinal Malignancies
Education
- MD, New York University
Residencies
- Internal Medicine - Columbia University Medical Center
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
- Medicine - Weill Cornell Medical College
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Yaeger sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Yaeger
- A Phase 1 Study of PF-07799933 Alone or with Binimetinib or Cetuximab in People with Solid Tumors
- A Phase 1/2 Study of BBI-825 in People With Advanced Solid Tumors
- A Phase 1/2 Study of FOG-001 in People With Advanced Cancer
- A Phase 2/3 Study of BRAF-Targeted Therapy After Surgery and Chemotherapy for BRAF-Mutated Colon Cancer
Read more
- A Phase I/II Study of MRTX849 in Patients with KRAS G12C-positive Cancers
- A Phase IB Study of AMG 510 Combined with Other Drugs to Treat Metastatic Solid Tumors with the KRAS G12C mutation
- A Phase II Study of Different Treatments for People with Stage III Colon Cancer Who Received Chemotherapy and Are Having Testing for Tumor DNA in the Blood
- Clinical Trials Co-Investigated by Dr. Yaeger
- A Phase 1 Study of CFT1946 in People With Solid Tumors Containing Mutations in BRAF-V600
- A Phase 1 Study of RMC-9805 in People With Solid Tumors
- A Phase 1 Study of SNDX-5613 in People With Advanced Colorectal Cancer and Other Digestive Tumors
- A Phase 1/2 Study of MRTX1133 in People With Solid Tumors That Have a KRAS G12D Gene Mutation
- A Phase 2 Study of FORE8394 in People Who Have Cancer With BRAF Mutations
- A Phase 2 Study of Ulixertinib for People With Histiocytic Neoplasms
- A Phase I Study of ASP3082 in People with Solid Tumors with KRAS G12D Mutations
- A Phase I Study of BGB-3245 in Patients with Metastatic Solid Tumors that Continue to Grow Despite Treatment
- A Phase I Study of LY3537982 in People with Solid Tumors with a G12C Mutation in the KRAS Gene
- A Phase I Study of RMC-6236 in People with Advanced Solid Tumors Containing Specific KRAS Mutations
- A Phase II Study of Tucatinib and Trastuzumab Followed by Chemotherapy as Initial Treatment for Locally Advanced HER2-Positive Rectal Cancer
- A Phase III Study of Tucatinib with Trastuzumab and mFOLFOX6 Chemotherapy versus Standard Care as Initial Treatment for HER2+ Metastatic Colorectal Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Yaeger’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Rona Yaeger discloses the following relationships and financial interests:
-
Lilly Oncology
Professional Services and Activities -
Mirati Therapeutics
Professional Services and Activities
-
Revolution Medicines
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].